SR-B1 targeted polypeptide compound and application thereof in preparation of antitumor drugs and immunotherapy sensitizer
Resiquimod is delivered specifically to the tumor site through the SR-B1 targeting peptide complex to regulate cholesterol metabolism, solving the problems of the single mechanism of action and immune system disorder of existing PD-L1 inhibitors, and achieving tumor suppression and immunotherapy sensitization effects.
Patent Information
- Application Number
- CN202510781553.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-06-12
- Publication Date
- 2025-09-05
AI Technical Summary
Existing PD-L1 inhibitors have a single mechanism of action, which leads to insufficient specific enrichment in tumor sites, easily triggers immune system disorders, and has limited therapeutic effects.
An SR-B1 targeting peptide complex was designed, consisting of an SR-B1 targeting peptide and the Toll-like receptor 7/8 agonist Resiquimod. The hydrophobic part of the SR-B1 targeting peptide aggregated to form nanospherical micelles that encapsulate Resiquimod, achieving tumor-site-specific delivery, activating the immune response, and regulating cholesterol metabolism to inhibit PD-L1 expression.
It achieves tumor site-specific drug enrichment, significantly inhibits tumor progression and immunosuppression, enhances tumor immunotherapy sensitivity, improves treatment efficacy and quality of life, and is biosafe.